Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion - Phase2 study of CBDCA / Nab-PAC + Bevacizumab to non-small-cell lung cancer with malignant pleural efussion

Osaka Prefectural Medical Center for Respiratory and Allergic diseases0 sites20 target enrollmentMarch 5, 2014

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion in stage4
Sponsor: Osaka Prefectural Medical Center for Respiratory and Allergic diseases
Enrollment: 20
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

March 5, 2014

End Date

March 31, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Osaka Prefectural Medical Center for Respiratory and Allergic diseases

•1\)History of pleurodesis or pleural effusion drainage 2\)Severe infection except for non\-active hepatitis C 3\)Fever more than 38 degree 4\)Severe comorbidity (heart failure/kidney failure/hepatic failure/uncontrollable diabetes/uncontrollable hypertension, etc) 5\)Active double cancer 6\)Symptomatic brain metastasis 7\)History of hemoptysis with 2\.5mL or more 8\)Pericardial effusion requiring drainage 9\)Interstitial pneumonia or pulmonary fibrosis detectable on X ray 10\)History of drug sensitivity 11\)Pregnant or lactating women 12\)Psychiatric disease or mental trouble 13\)Continuing administration of steroid 14\)Evaluated to be ineligible by a physician for other reasons